title: The use of topical aqueous suppressants in the prevention of postoperative intraocular pressure elevation after pars plana vitrectomy with long-acting gas tamponade.
abstract: OBJECTIVE
  To determine whether topical aqueous suppressant therapy applied after pars plana vitrectomy with gas tamponade prevents postoperative intraocular pressure (IOP) elevation.
  
  
  METHODS
  Prospective, nonrandomized comparative study.
  
  
  METHODS
  Forty-one patients who met inclusion criteria and underwent pars plana vitrectomy with gas tamponade (SF6 18%-20% or C3F8 12%-16%) over a 1-year period.
  
  
  METHODS
  Treatment eyes received topical aqueous suppressants at the end of surgery.
  
  
  METHODS
  Postoperative IOP at 4 to 6 hours, 1 day, and 1 week.
  
  
  RESULTS
  Twenty-one control and 20 treatment eyes met the inclusion criteria. The IOP (in mmHg) measured at 4 to 6 hours (23.05 [control, 14.73 [treatment]) and 1 day (23.24 [control], 17.28 [treatment]) postoperatively showed a statistically significant difference between the groups (P = 0.0038) at 4 to 6 hours and a trend toward significance (P = 0.057) at 1 day. Eleven control and three treatment eyes had an IOP spike above 25 mmHg at 4 to 6 hours or 1 day postoperatively (P = 0.02), and six control eyes and one treatment eye had postoperative IOP greater than 30 mmHg. A pressure rise greater than 40 mmHg was seen in two control eyes and no treatment eyes.
  
  
  CONCLUSIONS
  Use of topical aqueous suppressants after pars plana vitrectomy with long-acting gas tamponade is effective in preventing significant postoperative IOP elevation in most cases.
authors.affiliation: Vitreoretinal Section of the Eye Institute, Medical College of Wisconsin, Milwaukee, USA.
authors.forename: R A
authors.initials: RA
authors.lastname: Mittra
authors.forename: J S
authors.initials: JS
authors.lastname: Pollack
authors.forename: S
authors.initials: S
authors.lastname: Dev
authors.forename: D P
authors.initials: DP
authors.lastname: Han
authors.forename: W F
authors.initials: WF
authors.lastname: Mieler
authors.forename: J S
authors.initials: JS
authors.lastname: Pulido
authors.forename: T B
authors.initials: TB
authors.lastname: Connor
mesh_terms: D000287:Administration, Topical; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001082:Aqueous Humor / Q000187:drug effects*; D000068438:Brimonidine Tartrate; D003000:Clonidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D005466:Fluorocarbons / Q000008:administration & dosage*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D009798:Ocular Hypertension / Q000209:etiology / Q000517:prevention & control*; D011446:Prospective Studies; D011810:Quinoxalines / Q000008:administration & dosage / Q000627:therapeutic use; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use; D013459:Sulfur Hexafluoride / Q000008:administration & dosage*; D013876:Thiophenes / Q000008:administration & dosage / Q000627:therapeutic use; D013999:Timolol / Q000008:administration & dosage / Q000627:therapeutic use; D014821:Vitrectomy / Q000009:adverse effects*
chemical_list: D000959:Antihypertensive Agents; D005466:Fluorocarbons; D011810:Quinoxalines; D013449:Sulfonamides; D013876:Thiophenes; D000068438:Brimonidine Tartrate; D013999:Timolol; C016986:apraclonidine; C062765:dorzolamide; C042852:perflutren; D003000:Clonidine; D013459:Sulfur Hexafluoride